Companies sponsors |
Gilead Sciences Ltd (brexucabtagene autoleucel) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
Lymphoma Action |
Professional groups |
Association of Cancer Physicians |
|
Cancer Research UK |
|
Royal College of Physicians |
|
Royal College of Radiologists |
Comparator companies |
Baxter Healthcare (cyclophosphamide, doxorubicin)- No CAU- Not participating |
|
BeiGene UK (zanubrutinib)- CAU signed- Participating |
|
Celltrion Healthcare UK (rituximab)- No CAU- Not participating |
|
Dr Reddy’s Laboratories UK (bendamustine)- No CAU- Not participating |
|
Hospira UK (cytarabine, vincristine)- No CAU- Not participating |
|
Jazz Pharmaceuticals UK (cytarabine)- No CAU- Not participating |
|
Medac GmbH (doxorubicin)- No CAU- Not participating |
|
Pfizer (rituximab, doxorubicin)- No CAU- Not participating |
|
Roche (rituximab)- No CAU- Not participating |
|
Sandoz (rituximab, cyclophosphamide)- No CAU- Not participating |
|
Seacross Pharmaceuticals (bendamustine, doxorubicin)- No CAU- Not participating |
|
Zentiva (bendamustine)- No CAU- Not participating |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Cell and Gene Therapy Catapult |
|
Department of Health - Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |